Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
All content for Can We End Epidemics? is the property of Foreign Policy and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
Is it possible to end HIV and global health epidemics by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding.
Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
Can We End Epidemics?
Is it possible to end HIV and global health epidemics as public health threats by 2030? The United Nations thinks so, and the guests on this podcast series certainly hope so. But it’s going to take effort, innovation, connections between people and within communities and funding. Welcome to Can We End Epidemics?, a podcast series by the global biopharmaceutical company ViiV Healthcare in association with its biopharma majority shareholder GSK and developed by FP Studios.
